TerminatedPhase 2NCT00565656
A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts
Studying Myelodysplastic neoplasm with increased blasts
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Principal Investigator
- Laurence LEGROS, DoctorCentre Hospitalier Universitaire de Nice
- Intervention
- BEVACIZUMAB(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 60 years · All sexes
- Timeline
- 2007 – 2010
Study locations (10)
- Department of clinical hematology, Avignon, France
- Department of Hematology, Bobigny, France
- Department of Hematology, Lyon, France
- Paoli-Calmette Institut, Marseille, France
- Department of Clinical hematology, Archet Hospital, CHU de Nice, Nice, France
- Department of Onco-Hematology, Caremeau Hospital, CHU Nîmes, Nîmes, France
- Department of clinical hematology, Robert Debré Hospital, Reims, France
- Department of Hematology and Oncology, CHU de Strasbourg, Strasbourg, France
- Service de Médecine Interne, Toulouse, France
- Department of clinical hematology, Vandœuvre-lès-Nancy, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00565656 on ClinicalTrials.govOther trials for Myelodysplastic neoplasm with increased blasts
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06616636A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)M.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT06138587Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationDana-Farber Cancer Institute
- ACTIVE NOT RECRUITINGPHASE2NCT04994808Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid LeukemiaFred Hutchinson Cancer Center
- RECRUITINGPHASE2NCT04741945Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDSKirsten Grønbæk
- RECRUITINGPHASE1NCT04275518A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.Ascentage Pharma Group Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT03974217Talazoparib for Cohesin-Mutated AML and MDS With Excess BlastsDana-Farber Cancer Institute
- ACTIVE NOT RECRUITINGPHASE3NCT03682536A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA NaïveCelgene
- RECRUITINGPHASE1, PHASE2NCT03471260Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesM.D. Anderson Cancer Center
See all trials for Myelodysplastic neoplasm with increased blasts →